Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? This biotech might have a bright future, but it'll need to survive against the incumbents to do so.
Here's Why Viking Therapeutics Stock Surged Higher in June Investors are growing more optimistic over the company's pipeline and the initiation of a Phase 1 trial with a new drug.
Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly? Novo Nordisk offers dividend income and MASH upside versus Lilly's high‑growth obesity lead.
The Artificial Intelligence Opportunity Beyond Big Tech: 3 Healthcare Stocks to Watch These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.
2 Underrated Weight Loss Stocks to Buy and Hold They look well-positioned to grab a slice of the fast-growing anti-obesity market.
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.
Novo Nordisk's Wegovy Pill Just Hit 3 Million Prescriptions. Is Wall Street Missing Something With This Beaten-Down Stock? Novo Nordisk has been telling investors that volume will eventually offset price cuts, and early results suggest investors should listen.
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.
Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock? These two healthcare leaders have a long history of competing against one another.
3 Under-the-Radar Stocks to Buy and Hold for a Decade All three could become highly prominent biotech companies within 10 years.
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.
Is Viking Therapeutics Stock Going to $100? Viking stock is known for soaring after positive news.
